TY - CHAP M1 - Book, Section TI - Overview A1 - Rees, David A1 - Lanzkron, Sophie M. A2 - Gladwin, Mark T. A2 - Kato, Gregory J. A2 - Novelli, Enrico M. PY - 2021 T2 - Sickle Cell Disease AB - Although sickle cell disease (SCD) is probably the most common severe genetic disorder in the world, there are still only 3 therapeutic interventions that have been convincingly shown to alter the natural history of the condition in clinical trials: penicillin prophylaxis (prevention of invasive pneumococcal disease), hydroxyurea (reduction of acute complications, primary stroke prevention), and regular blood transfusion (primary stroke prevention). Although there are other treatments that are undoubtedly beneficial, including vaccination, analgesia, intermittent blood transfusion for symptomatic anemia, and hematopoietic stem cell transplantation, the treatment options in SCD are currently very limited. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1179346034 ER -